PMID- 33190819
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 0013-7006 (Print)
IS  - 0013-7006 (Linking)
VI  - 47
IP  - 2
DP  - 2021 Apr
TI  - [Ketamine, psilocybin, and rapid acting antidepressant: new promise for 
      psychiatry?].
PG  - 171-178
LID - S0013-7006(20)30234-7 [pii]
LID - 10.1016/j.encep.2020.08.006 [doi]
AB  - The hypothesis of monoaminergic deficiency has long dominated the conceptual 
      framework for the development of new antidepressant strategies, but the limits of 
      conventional antidepressant treatments targeting monoaminergic signaling have 
      motivated the search for new antidepressant pathways. The success of ketamine in 
      the management of depressive disorders has provoked a renewed interest in 
      hallucinogenic substances such as psilocybin targeting the serotonergic signaling 
      5HT(2A) and neurosteroid allosteric modulator of gamma-aminobutyric acid (GABAA) 
      receptors such as brexanolone. Unlike conventional treatments, these modulators 
      of glutamatergic, serotonergic and GABAergic systems exert a rapid antidepressant 
      effect ranging from 24hours to a week. Apart from their clinical interest and the 
      fantasized search for a "miracle" molecule that jointly meets the expectations of 
      patients and clinicians, these new targets could lead to the identification of 
      potential new biomarkers for the development of rapid-acting antidepressants and 
      redefine therapeutic strategies in mood disorders.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Bottemanne, H
AU  - Bottemanne H
AD  - Control-Interoception-Attention team, Paris Brain Institute, Institut du Cerveau 
      (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/Inserm, Paris, France.; 
      Department of Psychiatry, Pitie-Salpetriere Hospital, Assistance 
      Publique-Hopitaux de Paris (APHP), Paris, France. Electronic address: 
      hugo.bottemanne@gmail.com.
FAU - Claret, A
AU  - Claret A
AD  - Department of Psychiatry, Pitie-Salpetriere Hospital, Assistance 
      Publique-Hopitaux de Paris (APHP), Paris, France.
FAU - Fossati, P
AU  - Fossati P
AD  - Control-Interoception-Attention team, Paris Brain Institute, Institut du Cerveau 
      (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/Inserm, Paris, France.; 
      Department of Psychiatry, Pitie-Salpetriere Hospital, Assistance 
      Publique-Hopitaux de Paris (APHP), Paris, France.
LA  - fre
PT  - Journal Article
TT  - Ketamine, psilocybine, et antidepresseurs d'action rapide : de nouvelles 
      promesses pour la psychiatrie?
DEP - 20201112
PL  - France
TA  - Encephale
JT  - L'Encephale
JID - 7505643
RN  - 0 (Antidepressive Agents)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - Antidepressive Agents/therapeutic use
MH  - Humans
MH  - *Ketamine/pharmacology/therapeutic use
MH  - Psilocybin/pharmacology/therapeutic use
MH  - *Psychiatry
OTO - NOTNLM
OT  - Antidepressant
OT  - Antidepresseur
OT  - Brexanolone
OT  - Depression resistante aux traitements
OT  - Esketamine
OT  - Esketamine
OT  - Ketamine
OT  - Ketamine
OT  - Major depressive disorder
OT  - Neurosteroid
OT  - Neurosteroide
OT  - Psilocybin
OT  - Psilocybine
OT  - Psychedelic
OT  - Psychedelique
OT  - Treatment resistant depression
OT  - Episode depressif caracterise
EDAT- 2020/11/17 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/11/16 05:29
PHST- 2020/03/05 00:00 [received]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/11/16 05:29 [entrez]
AID - S0013-7006(20)30234-7 [pii]
AID - 10.1016/j.encep.2020.08.006 [doi]
PST - ppublish
SO  - Encephale. 2021 Apr;47(2):171-178. doi: 10.1016/j.encep.2020.08.006. Epub 2020 
      Nov 12.